Evidence map›Paper›PMID 24595353›Full record

ArticlePloS one2014

Secreted Gaussia princeps luciferase as a reporter of Escherichia coli replication in a mouse tissue cage model of infection.

Mingyu Liu, Christina Blinn, Sarah M McLeod, John W Wiseman, Joseph V Newman, Stewart L Fisher, Grant K Walkup

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. TargetingBiofilm · 2025
    Article
  2. Article
  3. Gaussia Luciferase as a Reporter for Quorum Sensing inSensors (Basel, Switzerland) · 2020
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Mingyu LiuBiology Department, Infection Innovative Medicines, AstraZeneca R&D Boston, Waltham, Massachusetts, United States of America.
Christina BlinnBiology Department, Infection Innovative Medicines, AstraZeneca R&D Boston, Waltham, Massachusetts, United States of America.
Sarah M McLeodBiology Department, Infection Innovative Medicines, AstraZeneca R&D Boston, Waltham, Massachusetts, United States of America.
John W WisemanRAD-Transgenics, Discovery Sciences, AstraZeneca R&D Mölndal, Mölndal, Sweden.
Joseph V NewmanBiology Department, Infection Innovative Medicines, AstraZeneca R&D Boston, Waltham, Massachusetts, United States of America.
Stewart L FisherBiology Department, Infection Innovative Medicines, AstraZeneca R&D Boston, Waltham, Massachusetts, United States of America.
Grant K WalkupBiology Department, Infection Innovative Medicines, AstraZeneca R&D Boston, Waltham, Massachusetts, United States of America.
AstraZeneca (United States) · USAstraZeneca (Sweden) · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Measurement of bacterial burden in animal infection models is a key component for both bacterial pathogenesis studies and therapeutic agent research. The traditional quantification means for in vivo bacterial burden requires frequent animal sacrifice and enumerating colony forming units (CFU) recovered from infection loci. To address these issues, researchers have developed a variety of luciferase-expressing bacterial reporter strains to enable bacterial detection in living animals. To date, all such luciferase-based bacterial reporters are in cell-associated form. Production of luciferase-secreting recombinant bacteria could provide the advantage of reporting CFU from both infection loci themselves and remote sampling (eg. body fluid and plasma). Toward this end, we have genetically manipulated a pathogenic Escherichia coli (E. coli) strain, ATCC25922, to secrete the marine copepod Gaussia princeps luciferase (Gluc), and assessed the use of Gluc as both an in situ and ex situ reporter for bacterial burden in mouse tissue cage infections. The E. coli expressing Gluc demonstrates in vivo imaging of bacteria in a tissue cage model of infection. Furthermore, secreted Gluc activity and bacterial CFUs recovered from tissue cage fluid (TCF) are correlated along 18 days of infection. Importantly, secreted Gluc can also be detected in plasma samples and serve as an ex situ indicator for the established tissue cage infection, once high bacterial burdens are achieved. We have demonstrated that Gluc from marine eukaryotes can be stably expressed and secreted by pathogenic E. coli in vivo to enable a facile tool for longitudinal evaluation of persistent bacterial infection.

Indexed as

Genes, ReporterAnimalsBiocatalysisChromosomes, BacterialColony Count, MicrobialCopepodaDisease Models, AnimalErwiniaEscherichia coliEscherichia coli InfectionsGenetic LociImaging, Three-DimensionalLuciferasesLuminescenceMicePolysaccharide-LyasesLuciferasespectate lyasePolysaccharide-Lyases

Identifiers

PMID24595353
PMCPMC3942414
OpenAlexW2100429982

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.